Oncology-focused CRO OncoBay has signed up to use physIQ’s latest patient monitoring system to track participants during their clinical trial journey.
PhysIQ, which focuses on patient monitoring and analytics, unveiled its latest offering for CROs and other life sciences research groups and drug developers that provides near real-time patient data.
physIQ Launches the Intrepid Partner Program
Remote patient monitoring and analytics leader physIQ and CRO Syneos Health are teaming up for a phase 3 trial of InCarda Therapeutics’ inhaled cardiovascular treatment InRhythm (flecainide) for patients with atrial fibrillation.
CHICAGO--(BUSINESS WIRE)--A leader in continuous remote patient monitoring and data analytics, physIQ today announced a strategic collaboration with InCarda Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases. Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, recommended physIQ’s innovative monitoring solution to help advance InCarda’s clinical study of InRhythm™ (orally inhaled flecainide) in patients with atrial fibrillation (AF) – one of the most common heart arrhythmias that affects one in four adults over the age of 40.1